<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Optimark II-31 - EN PI (annotated)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h2
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	line-height:150%;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
span.DocSubchapterChar
	{mso-style-name:"DocSubchapter Char";
	font-family:"Times",serif;
	font-weight:bold;}
span.EmailStyle39
	{mso-style-name:EmailStyle39;
	font-family:"Bookman Old Style",serif;
	color:blue;
	font-weight:normal;
	font-style:normal;
	text-decoration:none none;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BODYTEXTChar, li.BODYTEXTChar, div.BODYTEXTChar
	{mso-style-name:"BODY TEXT Char";
	margin:0in;
	text-align:justify;
	line-height:150%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:842.0pt 595.35pt;
	margin:70.9pt 56.7pt 70.9pt 56.7pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection3
	{page:WordSection3;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><a name="_Toc133804118"><span lang=EN-GB><img width=21
height=18 src="Optimar_files/image003.gif" alt="*">This medicinal product is
subject to additional monitoring. This will allow quick identification of new
safety information. Healthcare professionals are asked to report any suspected
adverse reactions. See section 4.8 for how to report adverse reactions.</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><a name="_Toc133804119"><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></a></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pre-filled syringe</span></u></p>

<p class=MsoNormal><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide,
equivalent to 500 micromol<a name="OLE_LINK10"></a><a name="OLE_LINK11">.</a></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 10 ml syringe contains 3309 mg
gadoversetamide equivalent to 5 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 15 ml syringe contains 4963.5 mg
gadoversetamide equivalent to 7.5 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 20 ml syringe contains 6618 mg
gadoversetamide equivalent to 10 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 30 ml syringe contains 9927 mg
gadoversetamide equivalent to 15 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient(s) with known effect</span></u><span
lang=EN-GB>:</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>30 ml of the solution contain 43.13 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide,
equivalent to 500 micromol.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each 10 ml vial contains 3309 mg
gadoversetamide equivalent to 5 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 15 ml vial contains 4963.5 mg
gadoversetamide equivalent to 7.5 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 20 ml vial contains 6618 mg
gadoversetamide equivalent to 10 millimol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient(s) with known effect:</span></u></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><a name="_Toc133804120"><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></a></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pre-filled syringe</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Solution for injection in pre-filled
syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Solution for injection in vial.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Clear, colourless to pale yellow solution.</span></p>

<p class=MsoNormal><span lang=EN-GB>pH: 6.0 &#8211; 7.5</span></p>

<p class=MsoNormal><span lang=EN-GB>Osmolality (37&deg;C): 1000 &#8211; 1200
mOsm/kg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><a
name="_Toc133804121"><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></a></h1>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Toc133804122"></a><a
name="_Toc145836071"><span lang=EN-GB>&nbsp;</span></a></p>

<h2><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>This
medicinal product is for diagnostic use only.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Optimark is
indicated for use with magnetic resonance imaging (MRI) of the central nervous
system (CNS) and liver. It provides contrast enhancement and facilitates
visualization and helps with the characterization of focal lesions and abnormal
structures in the CNS and liver in adult patients and in children of two years
and older with known or highly suspected pathology.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804123"></a><a name="_Toc145836072"><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should only be administered by
physicians experienced in clinical MRI practice.</span></p>

<p class=MsoNormal><span lang=EN-GB>To enable immediate action in emergencies,
the necessary medicinal products (e.g. epinephrine/ adrenaline, theophylline,
antihistamines, corticosteroids and atropines), endotracheal tube and
ventilator must be immediately available.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The agent should be administered as a bolus
peripheral intravenous injection at a dose of 0.2 ml/kg (100&nbsp;micromol/kg)
body weight. To ensure complete injection of the contrast medium, the injection
should be followed by a 5 ml flush of sodium chloride 9 mg/ml (0.9 %) solution
for injection. The imaging procedure should be completed within 1 hour of
administration of the contrast medium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Repeat dose</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In cranial MRI, if a strong clinical
suspicion of a lesion persists despite a single dose contrast-enhanced MRI or
when more accurate information on the number, size or extent of lesions might
influence management or therapy of the patient, in subjects with normal renal
function, a second bolus injection of 0.2ml/kg (100 micromol/kg) may be
administered within 30 minutes of the first injection as it may increase the
diagnostic yield of the examination.</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety of repeat doses has not been
established in children and adolescents (2 years and older), in patients with
renal impairment, or the elderly. The repeat dose is not recommended in these
populations.</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited data with other gadolinium contrast
agents suggests that for the exclusion of additional cranial metastases <a
name="OLE_LINK16"></a><a name="OLE_LINK17">in a patient with a known solitary
resectable metastasis, an MR exam with the injection of the dose </a>of 300
micromol/kg body weight of Optimark may lead to higher diagnostic confidence.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediactric population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is considered necessary
in children more than 2 years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is contraindicated in neonates up
to 4 weeks of age (see section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>Use of Optimark is not recommended in
children less than 2 years of age<u> </u>because the safety, efficacy, and
impact of immature kidney function have not been studied in this age group.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
(aged 65 years and above)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is considered necessary.
Caution should be exercised in elderly patients</span><span lang=EN-GB
style='color:black'> (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal and
hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is contraindicated in patients
with severe renal impairment (GFR &lt; 30 ml/min/1.73m<sup>2</sup>) and/or
acute renal injury <span style='color:black'>and in patients who have had liver
transplantation or in patients in the perioperative liver transplantation
period</span> (see section 4.3). Optimark should only be used after careful
risk/benefit evaluation in patients with moderate renal impairment (GFR 30-59
ml/min/1.73m<sup>2</sup>) at a dose not exceeding 100&nbsp;micromol/kg body
weight (see section 4.4). More than one dose should not be used during a scan.
Because of the lack of information on repeated administration, Optimark
injections should not be repeated unless the interval between injections is at
least 7 days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The agent should be administered as a bolus
peripheral intravenous injection. To ensure complete injection of the contrast
medium, the injection should be followed by a 5 ml flush of sodium chloride 9
mg/ml (0.9 %) solution for injection. Insertion of a flexible in-dwelling
venous catheter is recommended, see section 4.4.</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark must not be administered with an
autoinjector to children of 2 to 11 years (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Precautions to be taken before handling
or administering the medicinal product</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The container and the solution should be
inspected prior to use as described in section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804124"><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to gadoversetamide or to
other gadolinium containing products, or to any of the excipients listed in
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is contraindicated</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>in patients with severe renal impairment <span style='color:black'>(GFR
&lt;30ml/min/1.73m<sup>2</sup>) and/or acute kidney injury,</span></span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='color:black'>in patients who have had liver transplantation
or </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='color:black'>in patients in the perioperative liver
transplantation period and </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='color:black'>in neonates up to 4 weeks of age </span><span
lang=EN-GB>(see section 4.4)<span style='color:black'>.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804125"></a><a name="_Toc145836073"><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with any paramagnetic contrast agent,
enhancement of MRI with gadoversetamide may impair the visualization of
existing lesions. Some of these lesions may be seen on unenhanced, non-contrast
MRI. Therefore, caution should be exercised when contrast enhanced scan
interpretation is made in the absence of a companion unenhanced MRI.</span></p>

<p class=MsoNormal><span lang=EN-GB>Before the examination, care must be taken
that patients are sufficiently hydrated. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hypersensitivity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Allergoid and other idiosyncratic reactions
also may occur with gadoversetamide, which could become manifest in form of cardiovascular,
respiratory and skin reactions (see section 4.8). Most of these reactions occur
within half an hour after administering the contrast medium. As with all other
contrast media of the same class, late reactions may occur (after hours or
days) in rare cases; however, none were reported in the completed clinical
trials.</span></p>

<p class=MsoNormal><span lang=EN-GB>If hypersensitivity reactions occur, the
administration of the contrast medium must be discontinued immediately and
intravenous treatment initiated, if necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>During the examination, supervision by a
physician is necessary and insertion of a flexible in-dwelling catheter is
recommended. To enable immediate action in emergencies, the necessary medicinal
products (e.g. epinephrine/adrenaline, theophylline, antihistamines, corticosteroids
and atropines), endotracheal tube and ventilator must be immediately available.</span></p>

<p class=MsoNormal><span lang=EN-GB>The risk of hypersensitivity reactions is
increased in the following cases:</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with allergic predisposition</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with bronchial asthma; in these
patients it is especially the risk of bronchospasm which is increased</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with a history of reactions to contrast
agents, including a previous history of reaction to iodine-based contrast
agents</span></p>

<p class=MsoNormal><span lang=EN-GB>Before the injection of contrast media,
patients should be asked whether they have any allergies (e.g. allergies to
seafood or medicinal products, hay fever, urticaria), whether they are
hypersensitive to contrast media and whether they have bronchial asthma.
Premedication with antihistamines and/or glucocorticoids may be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Patients taking beta-blockers</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It should be noted that patients using
beta-blockers do not necessarily respond to the beta-agonists usually used for
the treatment of hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patients
with cardiovascular disease</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In this
group of patients hypersensitivity reactions may be severe. Especially in
patients with serious heart diseases (e.g. severe heart failure, coronary
artery disease) cardiovascular reactions may deteriorate. However, these were
not evident from clinical trials with Optimark.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Central
nervous system disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In patients suffering from epilepsy or
brain lesions the likelihood of convulsions during the examination may be
increased. Precautions are necessary when examining these patients (e.g.
monitoring of the patient) and the equipment and medicinal products needed for
the rapid treatment of possible convulsions should be available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Patients with impaired renal function</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>Prior to administration of Optimark, all patients should be
screened for renal dysfunction by obtaining laboratory tests.</span></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of nephrogenic
systemic fibrosis (NSF) associated with use of Optimark and some
gadolinium-containing contrast agents in patients with acute or chronic severe
renal impairment (GFR &lt;30ml/min/1.73m<sup>2</sup>) and/or acute kidney
injury. Optimark is contraindicated in these patients (see section 4.3). <span
style='color:black'>Patients who have had or are undergoing liver
transplantation </span>are at particular risk since the incidence of acute
renal failure is high in this group<span style='color:black'>. Therefore,
Optimark must not be used in patients who have had or are undergoing liver
transplantation and in neonates (see section 4.3).</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The risk for
development of NSF in patients with moderate renal impairment</span><span
lang=EN-GB> (GFR 30&#8211;59 ml/min/1.73 m&sup2;) is unknown; therefore
Optimark should only be used after careful <span style='color:black'>risk-benefit
evaluation in patients with moderate renal impairment.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide is dialysable.
Haemodialysis shortly after Optimark administration may be useful at removing
Optimark from the body. There is no evidence to support the initiation of
haemodialysis for prevention or treatment of NSF in patients not already
undergoing haemodialysis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with baseline renal impairment,
acute kidney injury requiring dialysis has occurred with the use of Optimark. The
risk of acute kidney injury may increase with an increased dose of the contrast
agent. Administer the lowest dose possible for adequate imaging.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Children
and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark must not be administered with an
autoinjector. The required dose should be administered by hand to children of 2
to 11 years to avoid overdosage by mistake.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Neonates
and infants</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should not be used in children
below the age of two years. Safety and efficacy have not been studied in this
age group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>As the renal clearance of
</span><span lang=EN-GB>gadoversetamide</span><span lang=EN-GB
style='color:black'> may be impaired in the elderly, it is particularly
important to screen patients aged 65 years and older for renal dysfunction</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains less than 1
mmol sodium (23 mg) per dose of up to 17 ml, i.e. it is essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml vials and 15 ml vials contain less
than 1 mmol sodium; i.e. they are essentially &#8216;sodium free&#8216;.</span></p>

<p class=MsoNormal><span lang=EN-GB>Higher doses contain 1 mmol sodium or more,
which should be taken into consideration for patients on a controlled sodium
diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pre-filled syringe</span></u></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>30 ml of the solution contain 43.13 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Serum
iron and zinc</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Caution should be exercised because
transient decreases in serum iron and zinc parameters have been observed in
clinical trials. The clinical significance of this is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804126"><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; </span></a><a
name="OLE_LINK8"></a><a name="OLE_LINK9"><span lang=EN-GB>Interaction with
other medicinal products and other forms of interaction</span></a></h2>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>No formal
interaction studies have been performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark has been shown to cause
interference in the measurement of serum calcium using the
ortho-cresolphthalein complexone (OCP) colorimetric method. However, the
administration of gadoversetamide does not cause a true decrease in serum
calcium. In the presence of gadoversetamide, the OCP technique produces an
erroneous, low value for plasma calcium. The magnitude of this measurement
artefact is proportional to the concentration of gadoversetamide in the blood,
and in patients with normal renal clearance accurate values can be obtained
approximately 90 minutes following injection. In patients with compromised
renal function, clearance of gadoversetamide will be slowed and the
interference with calcium determination by OCP prolonged.&nbsp; Gadoversetamide
does not affect other methods of measuring serum calcium, such as the arsenazo
III colorimetric method, atomic absorption spectroscopy, and inductively
coupled plasma mass spectroscopy</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804127"></a><a name="_Toc145836074"><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There are no data from the use of gadoversetamide
in pregnant women. Animal studies do not indicate direct or indirect harmful
effects with respect to reproductive toxicity (see section 5.3). Optimark
should not be used during pregnancy unless the clinical condition of the woman
requires use of gadoversetamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is unknown whether gadoversetamide is
excreted in human milk. There is insufficient information on the excretion of
gadoversetamide in animal milk. A risk to the suckling child cannot be
excluded. Breast-feeding should be discontinued for at least 24 hours after the
administration of <span style='color:black'>Optimark.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data did not reveal special
hazards for humans based on conventional studies of reproductive toxicity.
Clinical studies on fertility have not been performed</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804130"></a><a name="_Toc145836075"><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark has no or negligible influence on
the ability to drive and use machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>Ambulant patients while driving vehicles or
operating machinery should take into account that acute dizziness may
uncommonly (&#8805;1/1,000 to &lt;1/100) occur (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804131"></a><a name="_Toc145836076"><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
Effects</span></a></h2>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Summary of
the safety profile</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Most of the adverse
reactions were of mild to moderate intensity and transient in nature. The most
common adverse reactions were dysgeusia, feeling hot, headache and dizziness.</span></p>

<p class=MsoNormal><span lang=EN-GB>The majority of adverse reactions observed
after the use of gadoversetamide were found to be adverse reactions of the
nervous system, followed by general adverse reactions, gastrointestinal
disorders/skin and subcutaneous tissue disorders. </span></p>

<p class=MsoNormal><span lang=EN-GB>Serious adverse reactions have been
reported and include anaphylactic reactions, cardiovascular reactions, and
allergic respiratory disorders. Treatment should be symptomatic and immediate
access to necessary medicinal products and emergency equipment should be
available should a serious event occur.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The following adverse reactions have been
reported from clinical trials and from post-marketing use of gadoversetamide.
Within each frequency grouping, undesirable effects are presented in order of
decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:41.95pt'>
   <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:41.95pt'>
   <p class=MsoNormal><b><span lang=EN-GB>System Organ Class (MedDRA)</span></b></p>
   </td>
   <td width="11%" style='width:11.48%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:41.95pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Common (&#8805;1/100 to &lt;1/10)</span></b></p>
   </td>
   <td width="15%" style='width:15.62%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:41.95pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Uncommon (&#8805;1/1,000 to
   &lt;1/100)</span></b></p>
   </td>
   <td width="20%" style='width:20.64%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:41.95pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Rare <br>
   (&#8805;1/10,000 to &lt;1/1,000)</span></b></p>
   </td>
   <td width="18%" style='width:18.32%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:41.95pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Very Rare (&lt;1/10,000)</span></b></p>
   </td>
   <td width="18%" style='width:18.3%;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt;height:41.95pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Immune System Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anaphylactic reaction</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Metabolism and Nutrition Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Decreased appetite </span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Psychiatric Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anxiety, Sleep disorder, Confusion and
  disorientation</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" style='width:18.3%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nervous System Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Headache, Dysgeusia </span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dizziness, Hypoaesthesia, Paraesthesia,
  Parosmia</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Convulsion, Tremor, Somnolence, Burning
  sensation</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Syncope</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Eye Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Erythema of eyelid, Eye pain, Vision
  blurred, Conjunctivitis, Ocular hyperaemia</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Ear and Labyrinth Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Tinnitus, Vertigo</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cardiac Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Palpitations, AV block first degree,
  Extrasystoles, Tachycardia, Arrhythmia</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vascular Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Flushing</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hypotension, Hypertension</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Respiratory, Thoracic and Mediastinal
  Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nasal congestion, Throat irritation</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dyspnoea, Dysphonia, Rhinorrhoea, Throat
  tightness, Bronchospasm, Cough, Laryngeal/pharyngeal oedema, Pharyngitis,
  Rhinitis, Sneezing</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Gastrointestinal Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nausea, Diarrhoea</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Salivary hypersecretion,, Abdominal pain,
  Constipation, Dry mouth</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Skin and Subcutaneous Tissue Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pruritus, Rash</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Urticaria, Cold sweat, Erythema,
  Hyperhidrosis </span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Periorbital oedema</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Nephrogenic systemic fibrosis
  (NSF)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Renal and Urinary Disorders</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Blood creatinine increased, Haematuria</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>General Disorders and Administration Site
  Conditions</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Feeling hot</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Chest discomfort, Chest pain, Feeling
  cold (including peripheral coldness), Administration site reactions</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Chills, Pain, Face oedema, Asthenic
  conditions including asthenia, fatigue, and malaise, Fever, Oedema peripheral,
  Feeling abnormal</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" style='width:15.64%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="11%" style='width:11.48%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" style='width:15.62%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Blood calcium abnormal</span></p>
  </td>
  <td width="20%" style='width:20.64%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>ALT increased, Urine analysis abnormal,
  Urine electrolytes abnormal, albumin in urine, CPK Increased, Haemoglobin
  decreased</span></p>
  </td>
  <td width="18%" style='width:18.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Electrocardiogram QT prolonged</span></p>
  </td>
  <td width="18%" valign=top style='width:18.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal><span lang=EN-GB>Local reactions have occurred at the
injection site and may lead to local irritation type reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Cases of nephrogenic systemic
fibrosis (NSF) have been reported with Optimark (see section 4.4). Cases of
gadolinium associated skin plaques, with demonstrated sclerotic bodies on
histology, have been reported with some gadolinium-containing contrast agents
in patients who do not otherwise have symptoms or signs of nephrogenic systemic
fibrosis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark has been studied in children of 2
years and older with a similar safety profile as shown in the adult population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<h2><a name="_Toc133804132"></a><a name="_Toc145836077"><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide has been tested in humans
in doses up to 700 micromol/kg (seven times the standard dose). Clinical
consequences of an overdose have not been reported. Acute toxicity symptoms are
unlikely to occur in patients with normal renal function. Optimark can be
removed by haemodialysis. However, there is no evidence that haemodialysis is
suitable for prevention of <span style='color:black'>nephrogenic systemic fibrosis
(NSF)</span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><a name="_Toc133804133"><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></a><a name="_Toc133804134"></a><a name="_Toc145836078"></a></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic Group: MRI contrast
media, ATC code: V08CA06</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide is a chelate containing
gadolinium - which has paramagnetic properties and is responsible for the
contrast enhancement effect in MRI - and the ligand versetamide.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The purpose of an MRI contrast agent is to
induce signal intensity changes within the lesion thereby facilitating its
recognition from the surrounding normal structures. The use of a contrast agent
may therefore reduce the threshold for lesion detection and visualization.
Gadolinium containing MRI contrast agents (gadolinium-based chelates) are
designed to act indirectly on the local magnetic environment by altering proton
T1 (spin-lattice) and T2 (spin-spin) relaxation times and at the usual
concentration of 100 micromol/kg, the T1 shortening predominates, and the T2
shortening is not significant using T1-weighted sequences.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide, an extracellular
gadolinium chelate, after intravenous administration, equilibrates rapidly
within the extracellular fluid/space and is eliminated primarily by glomerular
filtration.</span></p>

<p class=MsoNormal><span lang=EN-GB>As a result of these characteristics, the
timing of the image acquisition after contrast administration is critical in
liver imaging. For liver metastases, the signal difference between the tumour
and surrounding liver tissue is significantly improved during the first 90
seconds after an extracellular gadolinium contrast agent is administered.
Therefore, a rapid imaging sequence should be initiated <a name="OLE_LINK18"></a><a
name="OLE_LINK19">20 seconds after bolus injection</a> of the contrast agent
when the agent is predominately in the hepatic arteries and then again at 60
seconds after injection during the dominant portal venous phase. Since the
hepatic artery and portal venous system supply approximately 20% and 80% of the
hepatic blood supply, respectively, the earlier (hepatic arterial phase) images
provide optimal lesion conspicuity for hypervascular lesions and the portal
venous phase images are useful for hypovascular lesions (most metastatic
lesions are relatively hypovascular and are better demonstrated during the
portal venous phase, manifesting as areas of lower signal intensity compared
with the markedly enhanced liver). Lesion conspicuity of hypo- and hypervascular
lesions may be reduced if imaging is delayed more than 3 minutes due to the
diffusion of the contrast agent into the interstitial spaces of both the liver
parenchyma and lesion (e.g. metastasis) making the lesion isointense with the
normal liver parenchyma. Delayed post-contrast or equilibrium images (&gt; 5
minutes after dosing) assist in the characterization of lesions, e.g. the
centre of a metastasis may accumulate contrast in the interstitial space of the
lesion and become hyperintense to the normal liver. This difference in
enhancement pattern is useful in formulating a differential diagnosis based on
lesion characterization and diagnostic confidence.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The enhancement of brain tumours using a
gadolinium (or iodine) containing contrast agent depends on the disruption of
the blood brain barrier (BBB). As a result, these agents have been referred to
as markers for sites of abnormal BBB breakdown. When the BBB is disrupted, the
gadoversetamide molecules diffuse into the interstitial compartment thereby
producing the characteristic paramagnetic effect of T1 and T2 shortening. In
general, the addition of contrast to MRI, at the standard clinical dose of 100
micromol/kg, has led to a significantly improved lesion detection, sensitivity
and diagnostic accuracy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804135"></a><a name="_Toc145836079"><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></a></h2>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of gadoversetamide
conforms to a two compartment open-model. At the 100 micromol/kg dose, the mean
distribution half life in normal subjects calculated by the method of residuals
in 12 normal volunteers is 13.3 &plusmn; 6.8 min. Mean volume of distribution
at the 100 micromol/kg dose in non-renally impaired patients (including both
normal subjects and patients with CNS or liver pathology) was 158.7 &plusmn;
29.0 to 214.3 (range 116.4 to 295.0) ml/kg. This volume of distribution
(approximately 10-15 l for a body weight of 70 kg) is consistent with a
medicinal product which distributes into the extracellular fluid. Dose level
has no consistent effect on the volume of distribution in any of the studies. Gadoversetamide
does not undergo protein binding in vitro.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The elimination half life at the 100
micromol/kg dose ranges from 1.49 &plusmn; 0.15 h in healthy volunteers to 2.11
&plusmn; 0.62 h in non-renally impaired patients (including normal subjects and
patients with CNS or liver pathology).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The mean plasma clearance of
gadoversetamide in healthy subjects (111.0 &plusmn; 14.1 ml/min/1.73m&sup2;<sup>
</sup>BSA) is not significantly different from the mean renal clearance.
Similar results are obtained in normal subjects and patients with various
combinations of liver, CNS and renal dysfunctions with renal clearance of
gadoversetamide being approximately 95% of the total plasma clearance. Such
results (ratio renal clearance/total plasma clearance close to 1) indicate that
gadoversetamide is essentially cleared through the kidneys.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There was no systematic difference in any
of the kinetic parameters as a function of dose level (100 to 700 micromol/kg).
Therefore, within this dose range, the kinetics of gadoversetamide appear to be
linear.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Metabolism</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The high accountability for the dose as
intact complex in urine suggests that no significant metabolism of
gadoversetamide occurs in humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Special Populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Effect of Gender:</span></p>

<p class=MsoNormal><span lang=EN-GB>Adult male and female subjects were
enrolled in two pharmacokinetic studies. No significant differences in
pharmacokinetics based on gender were identified.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Effects of Age:</span></p>

<p class=MsoNormal><span lang=EN-GB>When corrected for body weight, the total
body clearance of gadoversetamide is greater in the 2 to 11 year age group (143
&plusmn; 27.9 ml/h/kg) than that observed in the 12 to 18 year age group (117
&plusmn; 26.1 ml/h/kg) and the two adult populations (82.1 &plusmn; 16.8 and
56.5 &plusmn; 9.7 ml/h/kg in the 19 to 64 and &#8805; 65 year of age groups,
respectively).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The elimination half life in the 2 to 11
and 12 to 18 year age groups (1.4 &plusmn; 0.3 and 1.6&plusmn; 0.3 h<sup>-1</sup>,
respectively) is shorter than that observed in the two adult populations (1.9
&plusmn; 0.5 and 2.5&plusmn; 0.5 h<sup>-1</sup> in the 19 to 64 and &#8805; 65
year of age groups, respectively). The number of elderly patients in whom the
pharmacokinetics were determined was limited (over 65 years, N=3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Effect of
Renal Impairment</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide plasma levels increase
linearly with decreasing renal function; in patients with severe renal
impairment (Cr<sub>Cl</sub>&lt;30 ml/min) this even leads to a six-fold decreased
</span><span lang=EN-GB>gadoversetamide clearance and a corresponding six-fold
increased extent of exposure AUC and t<sub>&frac12;</sub>.&nbsp; Since
gadoversetamide is only administered as a single dose this will lead to a
longer and higher exposure for a limited duration. Still, after 72 hours even
in patients with severe renal impairment nearly the whole dose is recovered in
the urine and in healthy populations up to 500 micromol/kg doses were
administered without safety issues. Nevertheless, because of reported cases of
NSF that may be associated with renal impairment for other gadolinium
containing contrast agents and for gadoversetamide, Optimark should not be used
in these patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Nonclinical data reveal no special hazard
for humans based on conventional studies of safety pharmacology, acute
toxicity, reproductive toxicity, local tolerance, antigenicity, and
genotoxicity. No carcinogenicity studies were performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Repeated-dose toxicity studies in rats and
dogs revealed vacuolation of the tubular cells of the kidneys, with strong
evidence for reversibility of the effect. No functional impairment was
observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The elimination of Optimark in dogs younger
than 3 months of age was significantly delayed because of immature renal
function and resulted in a high systemic exposure to Optimark. &nbsp;Weekly
repeated dosing of two to twenty times the clinical dose from one week of age
through maturation resulted in extensive mineralization of tissues, which
produced localized effects, such as ulcerative dermatitis, compromised
circulation and hepatic dysfunction.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><a name="_Toc133804137"></a><a
name="_Toc145836080"><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></a></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Versetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>Calcium hydroxide</span></p>

<p class=MsoNormal><span lang=EN-GB>Calcium chloride dihydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium hydroxide and/or hydrochloric acid
for pH adjustment</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804138"></a><a name="_Toc145836081"><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the absence of compatibility studies,
Optimark should not be mixed with other medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804139"></a><a name="_Toc145836082"><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf-life</span></a></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Chemical and physical in-use stability has
been demonstrated for 24 hours at up to 25&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>From a microbiological point of view, the
product should be used immediately. If not used immediately, in-use storage
times and conditions prior to use are the responsibility of the user.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804140"></a><a name="_Toc145836083"><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></a></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pre-filled
syringe</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep the
syringe in the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep the
vial in the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Do not
refrigerate or freeze.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For storage
conditions after first opening of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><a name="_Toc133804141"></a><a name="_Toc145836084"><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></a></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pre-filled syringe</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is filled in pre-filled syringes
made of polypropylene. Syringe tip cap and piston are made of bromobutyl
rubber.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack sizes:</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 10 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 10
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 15 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 15
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 20 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 20
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 30 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 30
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Toc133804142"><span lang=EN-GB>Not all pack-sizes
may be marketed<b>.</b></span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is filled in vials made of
colourless highly resistant borosilicate glass (EP Type I). The vials are
fitted with bromobutyl rubber closures, aluminium cap seals, and plastic flip
caps.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pack sizes:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1 x 10 ml&nbsp;&nbsp;&nbsp;&nbsp; 10
x 10 ml</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1 x 15 ml&nbsp;&nbsp;&nbsp;&nbsp; 10
x 15 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 20 ml &nbsp;&nbsp;&nbsp; 10 x 20 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack-sizes may be marketed<b>.</b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB>Special
precautions for disposal and other handling</span></h2>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is intended for single use only;
any unused portions should be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use the solution if it is discoloured
or particulate matter is present. If non-disposable equipment is used,
scrupulous care should be taken to prevent residual contamination with traces
of cleansing agents.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pre-filled syringe</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pre-filled
syringes:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Assembly and
Inspection</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Inspect the
syringe for signs of leakage. Do not use if leakage is observed.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=328 style='width:246.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB><img
  border=0 width=297 height=105 id="Picture 1" src="Optimar_files/image004.jpg"
  alt="Pages from 1-3-1-spc-labelling-pil-01-spc-en"></span></p>
  </td>
  <td width=329 style='width:246.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>After
  screwing the push rod into the syringe piston, it is important to <b>turn the
  push rod an additional &frac12; turn</b> so that the grey piston rotates
  freely</span></p>
  </td>
 </tr>
 <tr>
  <td width=328 style='width:246.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=297 height=111
  id="Picture 2" src="Optimar_files/image005.jpg"
  alt="Pages from 1-3-1-spc-labelling-pil-01-spc-en"></span></p>
  </td>
  <td width=329 style='width:246.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Prior to using the syringe, twist off grey
  tip cap and discard. Syringe is now ready for needle or infusion tubing
  attachment.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard syringe and unused portion of the
solution after use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>The peel-off tracking label on the
pre-filled syringes should be stuck onto the patient record to enable accurate
recording of the gadolinium contrast agent used. The dose used should also be
recorded.</span></p>

<p class=MsoNormal><span lang=EN-GB>If electronic patient records are used, the
name of the product, the batch number and the dose should be entered into the
patient record.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should be drawn into the syringe
and used immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>The product must be examined before use to
confirm that all solids are dissolved and that the container and closure are
undamaged.&nbsp; If solids remain, the vial must be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard syringe and unused portion of the
solution after use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The peel-off tracking label on the vials
should be stuck onto the patient record to enable accurate recording of the
gadolinium contrast agent used. The dose used should also be recorded.</span><span
lang=EN-GB> </span><span lang=EN-GB>If electronic patient records are used, the
name of the product, the batch number and the dose should be entered into the
patient record.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><a name="_Toc133804143"><span lang=DE>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></a></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>Guerbet</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>15, rue des
Vanesses</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>93420
Villepinte</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>France</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><a name="_Toc133804144">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</a></h1>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><u>Pre-filled syringe</u></p>

<p class=MsoNormal>1 x 10 ml: EU/1/07/398/007</p>

<p class=MsoNormal><span lang=DE>10 x 10 ml: EU/1/07/398/008</span></p>

<p class=MsoNormal><span lang=DE>1 x 15 ml: EU/1/07/398/009</span></p>

<p class=MsoNormal><span lang=DE>10 x 15 ml: EU/1/07/398/010</span></p>

<p class=MsoNormal><span lang=DE>1 x 20 ml: EU/1/07/398/011</span></p>

<p class=MsoNormal><span lang=DE>10 x 20 ml: EU/1/07/398/012</span></p>

<p class=MsoNormal><span lang=DE>1 x 30 ml: EU/1/07/398/013</span></p>

<p class=MsoNormal><span lang=DE>10 x 30 ml EU/1/07/398/014</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=DE>Vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>1 x 10 ml:
EU/1/07/398/001</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>10 x 10 ml:
EU/1/07/398/002</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>1 x 15 ml:
EU/1/07/398/003</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>10 x 15 ml:
EU/1/07/398/004</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>1 x 20 ml:
EU/1/07/398/005</span></p>

<p class=MsoNormal style='page-break-after:avoid'>10 x 20 ml: EU/1/07/398/006</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<h1 style='page-break-after:avoid'><a name="_Toc133804145"><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></a></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 23 July 2007</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 15 June 2012</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><a name="_Toc133804146"><span lang=EN-GB>10.</span></a><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=center style='margin-left:0in;text-align:center;text-indent:0in'><span
lang=EN-GB>ANNEX II</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S) RESPONSIBLE FOR
BATCH RELEASE</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Mallinckrodt Medical Imaging Ireland</span></p>

<p class=MsoNormal><span lang=EN-GB>Damastown </span></p>

<p class=MsoNormal><span lang=EN-GB>Mulhuddart</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 15</span></p>

<p class=MsoNormal><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription. (See Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:13.0pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The requirements for submission of periodic
safety update reports for this medicinal product are set out in the list of
Union reference dates (EURD list) </span><span lang=EN-GB>provided for under
Article 107c(7) of Directive 2001/83</span><span lang=EN-GB>/EC</span><span
lang=EN-GB> and </span><span lang=EN-GB>any subsequent updates published on the
European medicines web-portal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid'><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The MAH shall
perform the pharmacovigilance activities detailed in the Pharmacovigilance
Plan, as agreed in RMP presented in Module 1.8.2 of the Marketing Authorisation
and any subsequent updates of the RMP agreed by the Committee for Medicinal
Products for Human Use CHMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>As per the CHMP
Guideline on Risk Management Systems for medicinal products for human use, the
updated RMP should be submitted at the same time as the next Periodic Safety
Update Report (PSUR).</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>In addition, an
updated RMP should be submitted</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>When new information is received that may impact
on the current Safety Specification, Pharmacovigilance Plan or risk
minimisation activities</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Within 60 days of an important
(pharmacovigilance or risk minimisation) milestone being reached</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Prior to the launch, the MAA shall provide
to all potential prescribers a copy of the SPC with a cover letter highlighting
the safety information included in Sections 4.3 and 4.4. The text shall be
agreed by the CHMP and shall also contain the following key element:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Optimark
is not recommended for use in children below the age of two years because the
safety, efficacy, and impact of immature kidney function have not been studied
in this age group. Optimark has been studied in children of 2 years and older
with a similar safety profile as shown in the adult population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;</span><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>Obligation to conduct
post-authorisation measures</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>The MAH shall complete, within the stated
timeframe, the following measures:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width="78%" valign=top style='width:78.88%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Description</span></b></p>
  </td>
  <td width="21%" valign=top style='width:21.12%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="78%" valign=top style='width:78.88%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The MAH shall submit <b>annual</b>
  cumulative reviews on nephrogenic systemic fibrosis (NSF) cases.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="21%" valign=top style='width:21.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>July of each year until the results of
  the study in bone have been submitted.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="78%" valign=top style='width:78.88%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>The MAH shall conduct a study evaluating the potential for
  long-term accumulation of gadolinium in the bone based on a CHMP agreed
  protocol.</p>
  </td>
  <td width="21%" valign=top style='width:21.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Final Study Report:<br>
  June 2018</span></p>
  </td>
 </tr>
</table>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 align=center style='text-align:center'><span lang=EN-GB>ANNEX III</span></h1>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Text for
the outer packaging of 10 ml, 15 ml, 20 ml and 30 ml pre-filled syringes</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide,
equivalent to 500 micromol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: versetamide, calcium hydroxide,
calcium chloride dihydrate, sodium hydroxide and/or hydrochloric acid, water
for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>Please see
package leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Solution
for <span style='background:silver'>injection</span></span><span lang=EN-GB
style='background:silver'> in pre-filled syringe</span></p>

<p class=MsoNormal><span lang=DE>10 ml (<span style='color:black;background:
#E0E0E0'>1</span>, 10 syringes)</span></p>

<p class=MsoNormal><span lang=DE>15 ml (<span style='color:black;background:
#E0E0E0'>1</span>, 10 syringes)</span></p>

<p class=MsoNormal><span lang=DE>20 ml (<span style='color:black;background:
#E0E0E0'>1</span>, 10 syringes)</span></p>

<p class=MsoNormal><span lang=EN-GB>30 ml (<span style='color:black;background:
#E0E0E0'>1</span>, 10 syringes)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contrast medium for magnetic resonance
imaging</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For recording: stick the peel-off tracking label
onto the patient record. For electronic records: enter product name, batch no.
and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;page-break-after:
avoid'><span lang=EN-GB>Keep the syringe in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;page-break-after:
avoid'><span lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For single use only. Discard any remaining
solution after first use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>Guerbet, 15,
rue des Vanesses, 93420 Villepinte, France</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/007 <span style='color:black;
background:#CCCCCC'>(1 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/008 <span style='color:black;
background:#CCCCCC'>(10 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/009 <span style='color:black;
background:#CCCCCC'>(1 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/010 <span style='color:black;
background:#CCCCCC'>(10 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/011 <span style='color:black;
background:#CCCCCC'>(1 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/012 <span style='color:black;
background:#CCCCCC'>(10 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/013 <span style='color:black;
background:#CCCCCC'>(1 x 30 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/014 <span style='color:black;
background:#CCCCCC'>(10 x 30 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subject to medical prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Not applicable.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black;background:silver'>Not applicable.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Text for
the immediate packaging of 15 ml, 20 ml and 30 ml pre-filled syringes</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide,
equivalent to 500 micromol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: versetamide, calcium hydroxide,
calcium chloride dihydrate, sodium hydroxide and/or hydrochloric acid, water
for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Solution
for <span style='background:silver'>injection</span></span><span lang=EN-GB
style='background:silver'> in pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>15 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>30 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This sticky label should be stuck on
patient records.</span></p>

<p class=MsoNormal><span lang=EN-GB>For electronic records: enter product name,
batch no. and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep the
syringe in the outer carton in order to protect from light.<br>
Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For single use only. Discard any remaining
solution after first use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Guerbet, 15, rue des Vanesses, 93420
Villepinte, France</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/007 <span style='color:black;
background:#CCCCCC'>(1 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/008 <span style='color:black;
background:#CCCCCC'>(10 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/009 <span style='color:black;
background:#CCCCCC'>(1 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/010 <span style='color:black;
background:#CCCCCC'>(10 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/011 <span style='color:black;
background:#CCCCCC'>(1 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/012 <span style='color:black;
background:#CCCCCC'>(10 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/013 <span style='color:black;
background:#CCCCCC'>(1 x 30 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/014 <span style='color:black;
background:#CCCCCC'>(10 x 30 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subject to medical prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Text for
the immediate packaging of the 10 ml pre-filled syringe</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for injection
in pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>IV use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the syringe in the outer carton in
order to protect from light.<br>
Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Text for
the outer packaging of 10 ml, 15 ml and 20 ml vials</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in vial</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide,
equivalent to 500 micromol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: versetamide, calcium hydroxide,
calcium chloride dihydrate, sodium hydroxide and/or hydrochloric acid, water for
injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>Solution
for injection in vial</span></p>

<p class=MsoNormal><span lang=DE>10 ml (<span style='color:black;background:
#D9D9D9'>1,</span> 10 vials)</span></p>

<p class=MsoNormal><span lang=DE>15 ml (<span style='color:black;background:
#D9D9D9'>1,</span> 10 vials)</span></p>

<p class=MsoNormal><span lang=DE>20 ml (<span style='color:black;background:
#D9D9D9'>1,</span> 10 vials)</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contrast medium for magnetic resonance imaging</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For recording: stick the peel-off tracking
label onto the patient record. For electronic records: enter product name,
batch no. and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep the
vial in the outer carton in order to protect from light.<br>
Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For single use only. Discard any remaining
solution after first use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Guerbet, 15, rue des Vanesses, 93420
Villepinte, France</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/001 <span style='color:black;
background:#CCCCCC'>(1 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/002 <span style='color:black;
background:#CCCCCC'>(10 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/003 <span style='color:black;
background:#CCCCCC'>(1 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/004 <span style='color:black;
background:#CCCCCC'>(10 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/005 <span style='color:black;
background:#CCCCCC'>(1 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/006 <span style='color:black;
background:#CCCCCC'>(10 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subject to medical prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Not applicable.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black;background:silver'>Not applicable.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Text for
the immediate packaging of 15 ml and 20 ml vials</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in vial</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide,
equivalent to 500 micromol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: versetamide, calcium hydroxide,
calcium chloride dihydrate, sodium hydroxide and/or hydrochloric acid, water
for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Solution
for injection</span><span lang=EN-GB style='color:black;background:#D9D9D9'> in
vial</span></p>

<p class=MsoNormal><span lang=EN-GB>15 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This sticky label should be stuck on
patient records.</span></p>

<p class=MsoNormal><span lang=EN-GB>For electronic records: enter product name,
batch no. and dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep the
vial in the outer carton in order to protect from light.<br>
Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For single use only. Discard any remaining
solution after first use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Guerbet, 15, rue des Vanesses, 93420
Villepinte, France</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/001 <span style='color:black;
background:#CCCCCC'>(1 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/002 <span style='color:black;
background:#CCCCCC'>(10 x 10 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/003 <span style='color:black;
background:#CCCCCC'>(1 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/004 <span style='color:black;
background:#CCCCCC'>(10 x 15 ml)</span></span></p>

<p class=MsoNormal><span lang=DE>EU/1/07/398/005 <span style='color:black;
background:#CCCCCC'>(1 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/07/398/006 <span style='color:black;
background:#CCCCCC'>(10 x 20 ml)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subject to medical prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#E0E0E0'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#E0E0E0'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Text for
the immediate packaging of the 10 ml vial</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark 500 micromol/ml solution for
injection in vial</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal><span lang=EN-GB>IV use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.<br>
Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Optimark
500 micromol/ml solution for injection in pre-filled syringe</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=21 height=18
src="Optimar_files/image003.gif">This medicine is subject to additional
monitoring. This will allow quick identification of new safety information. You
can help by reporting any side effects you may get. See the end of section 4
for how to report side effects.</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you are being given this medicine because it contains important
information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor
or pharmacist.</span><span lang=EN-GB style='color:blue'> </span><span
lang=EN-GB>This includes any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is in
this leaflet:</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Optimark is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you are given Optimark</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
Optimark is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Optimark</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Optimark is
and what it is used for</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark
contains the active substance gadoversetamide. Gadoversetamide is used as a
&#8216;contrast agent&#8217; in magnetic resonance imaging.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is for diagnostic use, only. It is
used in adult patients and children of two years and older, who are undergoing
magnetic resonance imaging (MRI), a type of scan where images of the internal
organs are taken. Optimark is used to obtain a clearer scan in patients who
have or are thought to have abnormalities in the brain, spine or liver.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to
know before you are given Optimark</span></h1>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
use Optimark</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>if you are allergic </span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>to the <u>active substance</u> gadoversetamide
or</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>to any of the <u>other ingredients</u> of
Optimark (see section 6), or</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>to other <u>gadolinium contrast agents.</u> </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>You must not be
given Optimark if </span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you suffer from severe and/or acute kidney
impairment, or </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:39.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if</span><span lang=EN-GB> you are a patient who
is about to have or has had a liver transplant as use of Optimark in patients
with these conditions has been associated with a disease called nephrogenic systemic
fibrosis (NSF). NSF is a disease involving thickening of the skin and
connective tissues. NSF may result in debilitating joint immobility, muscle
weakness or may affect the normal working of internal organs which may potentially
be life-threatening.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Optimark must not be used in newborn babies up
to the age of 4 weeks.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>Before you receive Optimark, you will need to have a blood
test to check how well your kidneys are working.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Talk to
your doctor before Optimark is used, if:</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>you suffer
     from allergies (e.g. medicinal products, seafood, hay fever, hives) or
     asthma</span></li>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>you had
     any reactions to previous injections of a contrast agent,</span><span
     lang=EN-GB> including a previous history of reaction to iodine-based
     contrast agents </span></li>
 <li class=MsoNormal><span lang=EN-GB>your kidneys do not work properly </span></li>
 <li class=MsoNormal><span lang=EN-GB>you have recently had, or soon expect to
     have, a liver transplant</span></li>
 <li class=MsoNormal><span lang=EN-GB>you are feeling thirsty and/or if you have
     only had small quantities or nothing to drink before the examination</span></li>
 <li class=MsoNormal><span lang=EN-GB>you are taking a special kind of antihypertensive
     medicine, i.e. a beta-blocker</span></li>
 <li class=MsoNormal><span lang=EN-GB>you have heart disease</span></li>
 <li class=MsoNormal><span lang=EN-GB>you suffer from epilepsy or brain lesions
     </span></li>
 <li class=MsoNormal><span lang=EN-GB>you are on a controlled sodium diet</span></li>
</ul>

<p class=MsoNormal><span lang=EN-GB>If any of these apply to you, your doctor
will decide whether the intended examination is possible or not.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is not recommended in children who
are below the age of two years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Other
medicines and Optimark</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Please tell your
doctor or pharmacist if you are taking or have recently taken any <u>other
medicines</u>, including medicines obtained without a prescription.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast-feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should not be used during
pregnancy unless strictly necessary. </span></p>

<p class=MsoNormal><span lang=EN-GB>Breast-feeding should be discontinued for
at least 24 hours after you receive Optimark. </span></p>

<p class=MsoNormal><span lang=EN-GB>If you are pregnant or breast-feeding, think
you may be pregnant or are planning to have a baby, ask your doctor for advice
before taking this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are an ambulant patient and plan to
drive or use tools or machines, take into account that dizziness may incidentally
occur after you undergo a procedure involving the injection of Optimark. Up to
1 in 100 people may be affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Optimark
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains less than 1
mmol sodium (23 mg) per dose of up to 17 ml, i.e. it is essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml vials and 15 ml vials contain less
than 1 mmol sodium; i.e. they are essentially &#8216;sodium free&#8216;.</span></p>

<p class=MsoNormal><span lang=EN-GB>Higher doses contain 1 mmol sodium or more,
which should be taken into consideration for patients on a controlled sodium
diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>30 ml of the solution contain 43.13 mg
sodium.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
Optimark is given</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Diagnostic
procedures involving the use of contrast agents should be conducted under
supervision of a physician with the prerequisite training and a thorough
knowledge of the procedure to be performed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>The usual dose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The usual dose of
0.2 ml/kg body weight is the same in adults and children of 2 years and older.
It would account for 14 ml for a 70 kg individual, and this volume would be
injected over about 7-14 seconds into a vein, usually a vein in an arm. The
injection is then flushed through with a saline injection to make sure none is
left in the needle or tube used for the injection. In adults, a second dose may
be given within 30 minutes of the first injection. When looking at certain
abnormalities in the brain, Optimark may need to be used at three times the
usual dose in one injection in adults. The doctor will decide how much Optimark
is needed for your examination. You must tell the doctor or nurse/technologist
immediately if you feel pain around the area where the needle is placed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Dosage in special patient groups</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In patients with
moderate kidney problems, more than one dose of Optimark should not be used
during a scan. Optimark injections should not be repeated unless the interval
between injections is at least 7 days.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>It is not
necessary to adjust your dose if you are 65 years of age or older but you will
have a blood test to check how well your kidneys are working.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you are
given more Optimark than you should have been</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If too much
Optimark was injected it is unlikely that it will do you much harm, as much
higher doses did not lead to any problems when some people received them. If
your kidneys are working normally it is unlikely you will have any problems.
Optimark can be removed using dialysis. If you think you have been injected
with too much Optimark, tell the doctor or nurse/technologist immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must report any of the following
symptoms immediately to the doctor or nurse/technologist, and get immediate
treatment as they can be or can become very serious: <br>
side effects affecting the heart (fainting, extra heart beats, chest pain) or
the respiratory system (shortness of breath, tightening of the airways, swollen
or tight throat, itchy or runny nose, sneezing).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Most of the side effects observed after the
use of Optimark were of mild to moderate intensity and transient in nature. The
most common side effects were a strange taste in the mouth, feeling hot,
headache and dizziness.</span></p>

<p class=MsoNormal><span lang=EN-GB>Possible side effects are described in
greater detail below.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The frequencies
below and the following symptoms are based on clinical trials, and on the
experience in using Optimark after it was on the market:</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=121 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
   lang=EN-GB>Frequency</span></b></p>
   </td>
   <td width=499 valign=top style='width:373.9pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Possible
   side effects</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Common (may
  affect up to 1 in 10 people)</span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>headache,
  strange taste in the mouth, feeling hot</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 100 people)</span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>allergic/hypersensitivity
  reaction, dizziness, tingling sensation, numbness, reduced sense of smell,
  skin red and warm, nasal congestion, sore throat, nausea, diarrhoea, itching,
  rash, chest discomfort, chest pain, feeling cold including cold feeling in
  extremities, administration site reactions, changes in blood calcium levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Rare</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 1000 people)</span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>decreased
  appetite, feeling anxious, sleep disorder, drowsy feeling, burning sensation,
  a sensation of movement or spinning, ringing in the ears, eyelid redness, eye
  pain, vision blurred, bloodshot eyes, awareness of the heartbeat, irregular
  heartbeats, extra heartbeats, low blood pressure, shortness of breath,
  hoarseness, runny nose, throat constriction, mouth watering, abdominal pain,
  constipation, dry mouth, hives, cold sweat, redness, higher blood level of a
  substance (creatinine) usually eliminated by the kidneys, blood in urine,
  face swollen, weakness and similar symptoms like fatigue and general feeling
  of being unwell, fever, swelling in limbs, chill, pain, cold feeling in
  extremities, liver enzyme increased, urine analysis abnormal, mineral values
  in urine increased, protein in urine, heart and muscle enzyme increased,
  decreased haemoglobin, feeling confused and disoriented, shaking, convulsion,
  pink eye, fast heart beat, high blood pressure, tightening of the airways,
  swollen throat or voice box, raw throat, cough, itchy nose, sneezing,
  sweating</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Very rare</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 10,000 people)</span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>swelling
  around the eyes, abnormal ECG heart tracing, fainting, vomiting</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Not known</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(frequency cannot
  be estimated from the available data)</span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>hardening of
  the skin which may affect also soft tissue and internal organs (nephrogenic
  systemic fibrosis), feeling unwell</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>There have been
reports of nephrogenic systemic fibrosis (which causes hardening of the skin
and may affect also soft tissue and internal organs).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>When Optimark
was used in children aged 2 or older they had similar side effects as in
adults.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Reporting of side effects</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you get any
side effects, talk to your doctor or pharmacist. This includes any possible
side effects not listed in this leaflet. </span><span lang=EN-GB>You can also
report side effects directly via <span style='background:silver'>the national
reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span></span><span lang=EN-GB>. By reporting side effects, you can help
provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Optimark</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the carton and on the syringe
label after EXP. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep the syringe
in the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not
refrigerate or freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The medicine should
be used immediately. If not used immediately, in-use storage times and
conditions prior to use are the responsibility of the user.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use the
solution if it is discoloured or particulate matter is present.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></h1>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>What Optimark contains</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:35.45pt;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The <u>active substance</u> is gadoversetamide.<br>
</span><span lang=EN-GB>1 ml contains 330.9 mg gadoversetamide, equivalent to
500 micromol.<br>
Each 10 ml syringe contains 3309 mg gadoversetamide.<br>
Each 15 ml syringe contains 4963.5 mg gadoversetamide.<br>
Each 20 ml syringe contains 6618 mg gadoversetamide.<br>
Each 30 ml syringe contains 9927 mg gadoversetamide.</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>The <u>other ingredients</u> are: versetamide, calcium
     hydroxide, calcium chloride dihydrate, sodium hydroxide and/or
     hydrochloric acid, water for injections.</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What Optimark
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark
syringes contain a clear, colourless to pale yellow solution.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
supplied in pre-filled syringes made of polypropylene. Syringe tip cap and
piston are made of bromobutyl rubber.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark
pre-filled syringes are supplied in the following package sizes:</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 10 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 10
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 15 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 15
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 20 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 20
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 30 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 30
ml</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Not all package
sizes may be marketed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>Guerbet</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>15, rue des Vanesses</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>93420 Villepinte</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>France</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the Marketing Authorisation Holder.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Manufacturer</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mallinckrodt
Medical Imaging Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damastown</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mulhuddart,
Dublin 15</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency (EMA) web site <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<div style='border:none;border-bottom:dashed windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>The following
information is intended for healthcare professionals only:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is indicated for use with magnetic
resonance imaging (MRI) of the central nervous system (CNS) and liver. It
provides contrast enhancement and facilitates visualization and helps with
characterization of focal lesions and abnormal structures in the CNS and liver in
adult patients and in children of two years and older with known or highly
suspected pathology.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Contraindications</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>Hypersensitivity to gadoversetamide or to other gadolinium
     containing products or to any of the excipients.</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>Optimark is contraindicated in patients with severe renal
     impairment (GFR &lt;&nbsp;30ml/min/1.73&nbsp;m<sup>2</sup>) and/or acute
     kidney injury, in </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>patients who have had liver transplantation or in </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>patients in the perioperative liver transplantation period and
     in </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>neonates up to 4 weeks of age.</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>As with any
paramagnetic contrast agent, enhancement of MRI with Optimark may impair the
visualization of existing lesions. Some of these lesions may be seen on
unenhanced, non-contrast MRI. Therefore, caution should be exercised when
contrast enhanced scan interpretation is made in the absence of a companion
unenhanced MRI.</span></p>

<p class=MsoNormal><span lang=EN-GB>Before the examination, care must be taken
that patients are sufficiently hydrated. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Hypersensitivity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Allergoid and other idiosyncratic reactions
also may occur with gadoversetamide, which could become manifest in form of
cardiovascular, respiratory and skin reactions. Most of these reactions occur
within half an hour after administering the contrast medium. As with all other
contrast media of the same class, late reactions may occur (after hours or
days) in rare cases; however, none were reported in the completed clinical
trials.</span></p>

<p class=MsoNormal><span lang=EN-GB>If hypersensitivity reactions occur, the
administration of the contrast medium must be discontinued immediately and
intravenous treatment initiated, if necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>During the examination, supervision by a
physician is necessary and insertion of a flexible in-dwelling catheter is
recommended. To enable immediate action in emergencies, the necessary medicinal
products (e.g. epinephrine/adrenaline, theophylline, antihistamines,
corticosteroids and atropines), endotracheal tube and ventilator must be
immediately available.</span></p>

<p class=MsoNormal><span lang=EN-GB>The risk of hypersensitivity reactions is
increased in the following cases:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with allergic predisposition</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with bronchial asthma; in these
patients it is especially the risk of bronchospasm which is increased</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with a history of reactions to contrast
agents, including a previous history of reaction to iodine-based contrast
agents</span></p>

<p class=MsoNormal><span lang=EN-GB>Before the injection of contrast media,
patients should be asked whether they have any allergies (e.g. allergies to
seafood or medicinal products, hay fever, urticaria), whether they are
hypersensitive to contrast media and whether they have bronchial asthma.
Premedication with antihistamines and/or glucocorticoids may be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Patients taking beta-blockers</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It should be noted that patients using
beta-blockers do not necessarily respond to the beta-agonists usually used for
the treatment of hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Patients with cardiovascular disease</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In this group of patients hypersensitivity
reactions may be severe. Especially in patients with serious heart diseases
(e.g. severe heart failure, coronary artery disease) cardiovascular reactions
may deteriorate. However, these were not evident from clinical trials with
Optimark.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Central nervous system disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In patients suffering from epilepsy or
brain lesions the likelihood of convulsions during the examination may be
increased. Precautions are necessary when examining these patients (e.g.
monitoring of the patient) and the equipment and medicinal products needed for
the rapid treatment of possible convulsions should be available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Patients with
impaired renal function</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Prior to
administration of Optimark, all patients should be screened for renal
dysfunction by obtaining laboratory tests.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>There have been
reports of nephrogenic systemic fibrosis (NSF) associated with use of Optimark
and some gadolinium-containing contrast agents in patients with acute or
chronic severe renal impairment (GFR &lt;&nbsp;30ml/min/1.73&nbsp;m&sup2;)
and/or acute kidney injury. Optimark is contraindicated in these patients (see
section Contraindications). Patients</span><span lang=EN-GB style='color:black'>
who have had or are undergoing liver transplantation are at particular risk
since the incidence of acute renal failure is high in this group. Therefore,
Optimark must not be used in patients who have had or are undergoing liver
transplantation and in neonates</span><span lang=EN-GB>. </span><span
lang=EN-GB style='color:black'>The risk for development of NSF in patients with
moderate renal impairment</span><span lang=EN-GB> (GFR 30&#8211;59 ml/min/1.73
m&sup2;) is unknown; therefore, Optimark should only be used after careful <span
style='color:black'>risk-benefit evaluation in patients with moderate renal
impairment</span>. Gadoversetamide is dialysable. Haemodialysis shortly after
Optimark administration may be useful at removing Optimark from the body. There
is no evidence to support the initiation of haemodialysis for prevention or
treatment of NSF in patients not already undergoing haemodialysis.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with baseline renal impairment,
acute kidney injury requiring dialysis has occurred with the use of Optimark.
The risk of acute kidney injury may increase with an increased dose of the
contrast agent. Administer the lowest dose possible for adequate imaging.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Children</span></u><u><span
lang=EN-GB> and adolescents</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark must
not be administered with an autoinjector. The required dose should be
administered by hand to children</span><span lang=EN-GB> of 2 to 11 years to
avoid overdosage by mistake.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Neonates
and infants</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark should
not be used in children below the age of two years. Safety and efficacy have
not been studied in this age group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>As the renal
clearance of gadoversetamide may be impaired in the elderly, it is particularly
important to screen patients aged 65 years and older for renal dysfunction.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains less than 1
mmol sodium (23 mg) per dose of up to 17 ml, i.e. it is essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml vials and 15 ml vials contain less
than 1 mmol sodium; i.e. they are essentially &#8216;sodium free&#8216;.</span></p>

<p class=MsoNormal><span lang=EN-GB>Higher doses contain 1 mmol sodium or more,
which should be taken into consideration for patients on a controlled sodium
diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>30 ml of the solution contain 43.13 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><u><span
lang=EN-GB>Serum iron and zinc</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Caution should be exercised because
transient decreases in serum iron and zinc parameters have been observed in
clinical trials. The clinical significance of this is unknown.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There are no data from the use of
gadoversetamide in pregnant women. Animal studies do not indicate direct or
indirect harmful effects with respect to reproductive toxicity. Optimark should
not be used during pregnancy unless the clinical condition of the woman
requires use of gadoversetamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is unknown whether gadoversetamide is
excreted in human milk. There is insufficient information on the excretion of
gadoversetamide in animal milk. A risk to the suckling child cannot be
excluded. Breast-feeding should be discontinued for at least 24 hours after the
administration of Optimark.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Nonclinical data did not reveal special
hazards for humans based on conventional studies of reproductive toxicity.
Clinical studies on fertility have not been performed.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Posology and
method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should only be administered by
physicians experienced in clinical MRI practice.</span></p>

<p class=MsoNormal><span lang=EN-GB>To enable immediate action in emergencies,
the necessary medicinal products (e.g. epinephrine/ adrenaline, theophylline,
antihistamines, corticosteroids and atropines), endotracheal tube and
ventilator must be immediately available.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The agent should
be administered as a bolus peripheral intravenous injection at a dose of 0.2
ml/kg (100 micromol/kg) body weight. To ensure complete injection of the
contrast medium, the injection should be followed by a 5 ml flush of sodium chloride
9 mg/ml (0.9 %) </span><span lang=EN-GB>solution for injection. The imaging
procedure should be completed within 1 hour of administration of the contrast
medium.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Repeat
dose</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In cranial MRI,
if a strong clinical suspicion of a lesion persists despite a single dose
contrast-enhanced MRI or when more accurate information on the number, size or
extent of lesions might influence management or therapy of the patient, </span><span
lang=EN-GB>in subjects with normal renal function, a second bolus injection of 0.2
ml/kg (100 micromol/kg) may be administered within 30 minutes of the first
injection as it may increase the diagnostic yield of the examination. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The safety of
repeat doses has not been established in children and adolescents (2 years and
older), in patients with renal impairment, or the elderly.</span><span
lang=EN-GB> The repeat dose is not recommended in these populations.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Limited data
with other gadolinium contrast agents suggests that for the exclusion of
additional cranial metastases in a patient with a known solitary resectable
metastasis, an MR exam with the injection of 300 micromol/kg body weight of
Optimark may lead to higher diagnostic confidence.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>No dose
adjustment is considered necessary in children more than 2 years of age.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
contraindicated in neonates up to 4 weeks of age. Use of Optimark is not
recommended in children less than 2 years of age<u> </u>because the safety,
efficacy, and impact of immature kidney function have not been studied in this
age group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>Elderly (aged
65 years and above)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>No dosage
adjustment is considered necessary. Caution should be exercised in elderly
patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><i><span
lang=EN-GB>Renal and hepatic impairment</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
contraindicated in patients with severe renal impairment (GFR &lt; 30
ml/min/1.73&nbsp;m<sup>2</sup>) and/or acute renal injury and in patients who
have had liver transplantation or in patients in the perioperative liver
transplantation period. Optimark should only be used after careful risk/benefit
evaluation in patients with moderate renal impairment (GFR 30-59 ml/min/1.73&nbsp;m<sup>2</sup>)
at a dose not exceeding 100&nbsp;micromol/kg body weight. More than one dose
should not be used during a scan. Because of the lack of information on
repeated administration, Optimark injections should not be repeated unless the
interval between injections is at least 7 days.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The agent should be administered as a bolus
peripheral intravenous injection. To ensure complete injection of the contrast
medium, the injection should be followed by a 5 ml flush of sodium chloride 9
mg/ml (0.9 %) solution for injection. Insertion of a flexible in-dwelling
venous catheter is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark must not be administered with an
autoinjector to children of 2 to 11 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Precautions to be taken before handling
or administering the medicinal product</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The container
and the solution should be inspected prior to use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Interaction with other medicinal products and other forms of
interaction</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>No formal
interaction studies have been performed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Gadoversetamide
has been shown to cause interference in the measurement of serum calcium using
the ortho-cresolphthalein complexone (OCP) colorimetric method. However, the
administration of gadoversetamide does not cause a true decrease in serum
calcium. In the presence of gadoversetamide, the OCP technique produces an
erroneous, low value for plasma calcium. The magnitude of this measurement
artefact is proportional to the concentration of gadoversetamide in the blood,
and in patients with normal renal clearance accurate values can be obtained
approximately 90 minutes following injection. In patients with compromised
renal function, clearance of gadoversetamide will be slowed and the
interference with calcium determination by OCP prolonged.&nbsp; Gadoversetamide
does not affect other methods of measuring serum calcium, such as the arsenazo
III colorimetric method, atomic absorption spectroscopy, and inductively
coupled plasma mass spectroscopy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Special
precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Optimark is
intended for single use only; any unused portions should be discarded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Do not use the solution if it is discoloured or particulate matter
is present. If non-disposable equipment is used, scrupulous care should be
taken to prevent residual contamination with traces of cleansing agents. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Pre-filled
syringes:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Assembly and
Inspection</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>Inspect the syringe for signs of leakage. Do not use if leakage is
observed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=328 style='width:246.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=297 height=105
  id="Picture 3" src="Optimar_files/image006.jpg"
  alt="Pages from 1-3-1-spc-labelling-pil-01-spc-en"></span></p>
  </td>
  <td width=329 style='width:246.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>After screwing the push rod into the
  syringe piston, it is important to <b>turn the push rod an additional
  &frac12; turn</b> so that the grey piston rotates freely.</span></p>
  </td>
 </tr>
 <tr>
  <td width=328 style='width:246.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=297 height=111
  id="Picture 4" src="Optimar_files/image007.jpg"
  alt="Pages from 1-3-1-spc-labelling-pil-01-spc-en"></span></p>
  </td>
  <td width=329 style='width:246.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Prior to using the syringe, twist off
  grey tip cap and discard. Syringe is now ready for needle or infusion tubing
  attachment.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Discard syringe
and unused portion of the solution after use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Any unused
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>The peel-off tracking label on the
pre-filled syringes should be stuck onto the patients record to enable accurate
recording of the gadolinium contrast agent used. The dose used should also be
recorded. </span></p>

<p class=MsoNormal><span lang=EN-GB>If electronic patient records are used, the
name of the product, the batch number and the dose should be entered into the
patient record.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Optimark
500 micromol/ml solution for injection in vial</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Gadoversetamide</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=21 height=18
src="Optimar_files/image003.gif">This medicine is subject to additional
monitoring. This will allow quick identification of new safety information. You
can help by reporting any side effects you may get. See the end of section 4
for how to report side effects.</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you are being given this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet:</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Optimark is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you are given Optimark</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
Optimark is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Optimark</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Optimark is
and what it is used for</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark
contains the active substance gadoversetamide. Gadoversetamide is used as a
&#8216;contrast agent&#8217; in magnetic resonance imaging.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is for
diagnostic use, only. It is used in adult patients and children of two years
and older, who are undergoing magnetic resonance imaging (MRI), a type of scan
where images of the internal organs are taken. Optimark is used to obtain a clearer
scan in patients who have or are thought to have abnormalities in the brain,
spine or liver.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to
know before you are given Optimark</span></h1>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Do not use Optimark</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>if you are allergic</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>to the <u>active substance</u> gadoversetamide
or</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>to any of the <u>other ingredients</u> of
Optimark (see section 6), or</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>to other <u>gadolinium contrast agents.</u> </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>You must not be
given Optimark if </span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you suffer from severe and/or acute kidney
impairment, or </span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are a patient who is about to have or has
had a liver transplant as use of Optimark in patients with these conditions has
been associated with a disease called nephrogenic systemic fibrosis (NSF). NSF
is a disease involving thickening of the skin and connective tissues. NSF may
result in debilitating joint immobility, muscle weakness or may affect the
normal working of internal organs which may potentially be life-threatening.</span></p>

<p class=MsoNormal style='margin-left:39.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Optimark must not be used in newborn babies up
to the age of 4 weeks. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>Before you receive Optimark, you will need to have a blood
test to check how well your kidneys are working.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Talk to
your doctor before Optimark is used, if:</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>you suffer
     from allergies (e.g. medicinal products, seafood, hay fever, hives) or
     asthma</span></li>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>you had
     any reactions to previous injections of a contrast agent,</span><span
     lang=EN-GB> including a previous history of reaction to iodine-based contrast
     agents </span></li>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>your
     kidneys do not work properly </span></li>
 <li class=MsoNormal><span lang=EN-GB>you have recently had, or soon expect to
     have, a liver transplant </span></li>
 <li class=MsoNormal><span lang=EN-GB>you are feeling thirsty and/or if you
     have only had small quantities or nothing to drink before the examination</span></li>
 <li class=MsoNormal><span lang=EN-GB>you are taking a special kind of
     antihypertensive medicine, i.e. a beta-blocker</span></li>
 <li class=MsoNormal><span lang=EN-GB>you have heart disease</span></li>
 <li class=MsoNormal><span lang=EN-GB>you suffer from epilepsy or brain lesions
     </span></li>
 <li class=MsoNormal><span lang=EN-GB>you are on a controlled sodium diet</span></li>
</ul>

<p class=MsoNormal><span lang=EN-GB>If any of these apply to you, your doctor
will decide whether the intended examination is possible or not.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is not recommended in children who
are below the age of two years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Other
medicines and Optimark</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Please tell your
doctor or pharmacist if you are taking or have recently taken any <u>other
medicines</u>, including medicines obtained without a prescription.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast-feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should not be used during
pregnancy unless strictly necessary. </span></p>

<p class=MsoNormal><span lang=EN-GB>Breast-feeding should be discontinued for
at least 24 hours after you receive Optimark. </span></p>

<p class=MsoNormal><span lang=EN-GB>If you are pregnant or breast-feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are an ambulant patient and plan to
drive or use tools or machines, take into account that dizziness may
incidentally occur after you undergo a procedure involving the injection of
Optimark. </span></p>

<p class=MsoNormal><span lang=EN-GB>Up to 1 in 100 people may be affected.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Optimark
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains less than 1
mmol sodium (23 mg) per dose of up to 17 ml, i.e. it is essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml vials and 15 ml vials contain less
than 1 mmol sodium; i.e. they are essentially &#8216;sodium free&#8216;.</span></p>

<p class=MsoNormal><span lang=EN-GB>Higher doses contain 1 mmol sodium or more,
which should be taken into consideration for patients on a controlled sodium diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg
sodium.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
Optimark is given</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Diagnostic procedures involving the use of
contrast agents should be conducted under supervision of a physician with the
prerequisite training and a thorough knowledge of the procedure to be
performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>The usual dose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The usual dose of
0.2 ml/kg body weight is the same in adults and children of 2 years and older. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>It would account
for 14 ml for a 70 kg individual, and this volume would be injected over about
7-14 seconds into a vein, usually a vein in an arm. The injection is then
flushed through with a saline injection to make sure none is left in the needle
or tube used for the injection. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In adults, a second
dose may be given within 30 minutes of the first injection. When looking at
certain abnormalities in the brain, Optimark may need to be used at three times
the usual dose in one injection in adults. The doctor will decide how much
Optimark is needed for your examination. You must tell the doctor or
nurse/technologist immediately if you feel pain around the area where the
needle is placed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Dosage in special patient groups</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In patients with
moderate kidney problems, more than one dose of Optimark should not be used
during a scan. Optimark injections should not be repeated unless the interval
between injections is at least 7 days.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>It is not
necessary to adjust your dose if you are 65 years of age or older but you will
have a blood test to check how well your kidneys are working.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you are
given more Optimark than you should have been</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If too much
Optimark was injected it is unlikely that it will do you much harm, as much
higher doses did not lead to any problems when some people received them. If
your kidneys are working normally it is unlikely you will have any problems.
Optimark can be removed using dialysis. If you think you have been injected
with too much Optimark, tell the doctor or nurse/technologist immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must report any of the following
symptoms immediately to the doctor or nurse/technologist, and get immediate
treatment as they can be or can become very serious: <br>
side effects affecting the heart (fainting, extra heart beats, chest pain) or
the respiratory system (shortness of breath, tightening of the airways, swollen
or tight throat, itchy or runny nose, sneezing).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Most of the side effects observed after the
use of Optimark were of mild to moderate intensity and transient in nature. The
most common side effects were a strange taste in the mouth, feeling hot,
headache and dizziness.</span></p>

<p class=MsoNormal><span lang=EN-GB>Possible side effects are described in
greater detail below.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The frequencies
below and the following symptoms are based on clinical trials, and on the
experience in using Optimark after it was on the market:</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Frequency</span></b></p>
   </td>
   <td width=489 valign=top style='width:366.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Possible
   side effects</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Common</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 10 people)</span></p>
  </td>
  <td width=489 valign=top style='width:366.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>headache,
  strange taste in the mouth, feeling hot</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 100 people)</span></p>
  </td>
  <td width=489 valign=top style='width:366.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>allergic/hypersensitivity
  reaction, dizziness, tingling sensation, numbness, reduced sense of smell,
  skin red and warm, nasal congestion, sore throat, nausea, diarrhoea, itching,
  rash, chest discomfort, chest pain, feeling cold including cold feeling in
  extremities, administration site reactions, changes in blood calcium levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Rare</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 1000 people)</span></p>
  </td>
  <td width=489 valign=top style='width:366.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>decreased
  appetite, feeling anxious, sleep disorder, drowsy feeling, burning sensation,
  a sensation of movement or spinning, ringing in the ears, eyelid redness, eye
  pain, vision blurred, bloodshot eyes, awareness of the heartbeat, irregular
  heartbeats, extra heartbeats, low blood pressure, shortness of breath,
  hoarseness, runny nose, throat constriction, mouth watering, abdominal pain,
  constipation, dry mouth, hives, cold sweat, redness, higher blood level of a
  substance (creatinine) usually eliminated by the kidneys, blood in urine,
  face swollen, weakness and similar symptoms like fatigue and general feeling
  of being unwell, fever, swelling in limbs, chill, pain, cold feeling in
  extremities, liver enzyme increased, urine analysis abnormal, mineral values
  in urine increased, protein in urine, heart and muscle enzyme increased,
  decreased haemoglobin, feeling confused and disoriented, shaking, convulsion,
  pink eye, fast heart beat, high blood pressure, tightening of the airways,
  swollen throat or voice box, raw throat, cough, itchy nose, sneezing,
  sweating</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Very rare</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(may affect up
  to 1 in 10,000 people)</span></p>
  </td>
  <td width=489 valign=top style='width:366.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>swelling
  around the eyes, abnormal ECG heart tracing, fainting, vomiting</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=130 valign=top style='width:97.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Not known</span></p>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>(frequency
  cannot be estimated from the available data)</span></p>
  </td>
  <td width=489 valign=top style='width:366.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>hardening of
  the skin which may affect also soft tissue and internal organs (nephrogenic
  systemic fibrosis), feeling unwell</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>There have been
reports of nephrogenic systemic fibrosis (which causes hardening of the skin
and may affect also soft tissue and internal organs).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>When Optimark
was used in children aged 2 or older they had similar side effects as in
adults.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Reporting of side effects</b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you get any
side effects, talk to your doctor or pharmacist. This includes any possible
side effects not listed in this leaflet.</span><span lang=EN-GB> You can also
report side effects directly</span><span lang=EN-GB> via </span><span
lang=EN-GB style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB>. By reporting side effects, you can help provide
more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Optimark</span></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the carton and on the vial
label after EXP. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not
refrigerate or freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The medicine
should be used immediately. If not used immediately, in-use storage times and
conditions prior to use are the responsibility of the user.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use the
solution if it is discoloured or particulate matter is present.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='page-break-after:avoid'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></h1>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>What Optimark contains</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:35.45pt;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The <u>active substance</u> is gadoversetamide.<br>
1 ml contains 330.9 mg gadoversetamide, equivalent to 500 micromol.<br>
</span><span lang=EN-GB>Each 10 ml vial contains 3309 mg gadoversetamide.<br>
Each 15 ml vial contains 4963.5 mg gadoversetamide.<br>
Each 20 ml vial contains 6618 mg gadoversetamide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:35.45pt;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The <u>other ingredients</u> are: versetamide,
calcium hydroxide, calcium chloride dihydrate, sodium hydroxide and/or
hydrochloric acid, water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What Optimark
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark vials
contain a clear, colourless to pale yellow solution.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
supplied in vials, fitted with bromobutyl rubber closures and aluminium cap
seals.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Optimark vials are supplied in the following package sizes:</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 10 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 10
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 15 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 15
ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 20 ml&nbsp;&nbsp;&nbsp;&nbsp; 10 x 20
ml</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Not all package
sizes may be marketed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>Guerbet</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>15, rue des Vanesses</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>93420 Villepinte</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt'><span
lang=FR>France</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the Marketing Authorisation Holder.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Manufacturer</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mallinckrodt
Medical Imaging Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damastown</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mulhuddart,
Dublin 15</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency (EMA) web site <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<div style='border:none;border-bottom:dashed windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>The following
information is intended for healthcare professionals only:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Therapeutic indications</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
indicated for use with magnetic resonance imaging (MRI) of the central nervous
system (CNS) and liver. It provides contrast enhancement and facilitates
visualization and helps with characterization of focal lesions and abnormal
structures in the CNS and liver in adult patients and in children of two years
and older with known or highly suspected pathology.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Contraindications</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>Hypersensitivity to gadoversetamide or to other gadolinium
     containing products or to any of the excipients.</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>Optimark is contraindicated in patients with severe renal
     impairment (GFR &lt;&nbsp;30ml/min/1.73&nbsp;m&sup2;) and/or acute kidney
     injury, in</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>patients who have had liver transplantation or in </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>patients in the perioperative liver transplantation period and
     in </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
     lang=EN-GB>neonates up to 4 weeks of age.</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>As with any
paramagnetic contrast agent, enhancement of MRI with Optimark may impair the
visualization of existing lesions. Some of these lesions may be seen on
unenhanced, non-contrast MRI. Therefore, caution should be exercised when
contrast enhanced scan interpretation is made in the absence of a companion
unenhanced MRI.</span></p>

<p class=MsoNormal><span lang=EN-GB>Before the examination, care must be taken
that patients are sufficiently hydrated. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hypersensitivity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Allergoid and other idiosyncratic reactions
also may occur with gadoversetamide, which could become manifest in form of
cardiovascular, respiratory and skin reactions. Most of these reactions occur
within half an hour after administering the contrast medium. As with all other
contrast media of the same class, late reactions may occur (after hours or
days) in rare cases; however, none were reported in the completed clinical
trials.</span></p>

<p class=MsoNormal><span lang=EN-GB>If hypersensitivity reactions occur, the
administration of the contrast medium must be discontinued immediately and
intravenous treatment initiated, if necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>During the examination, supervision by a
physician is necessary and insertion of a flexible in-dwelling catheter is
recommended. To enable immediate action in emergencies, the necessary medicinal
products (e.g. epinephrine/adrenaline, theophylline, antihistamines,
corticosteroids and atropines), endotracheal tube and ventilator must be
immediately available.</span></p>

<p class=MsoNormal><span lang=EN-GB>The risk of hypersensitivity reactions is
increased in the following cases:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with allergic predisposition</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with bronchial asthma; in these
patients it is especially the risk of bronchospasm which is increased</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>patients with a history of reactions to contrast
agents, including a previous history of reaction to iodine-based contrast
agents</span></p>

<p class=MsoNormal><span lang=EN-GB>Before the injection of contrast media, patients
should be asked whether they have any allergies (e.g. allergies to seafood or
medicinal products, hay fever, urticaria), whether they are hypersensitive to
contrast media and whether they have bronchial asthma. Premedication with
antihistamines and/or glucocorticoids may be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patients
taking beta-blockers</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It should be noted that patients using
beta-blockers do not necessarily respond to the beta-agonists usually used for
the treatment of hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Patients with cardiovascular disease</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In this group of patients hypersensitivity
reactions may be severe. Especially in patients with serious heart diseases
(e.g. severe heart failure, coronary artery disease) cardiovascular reactions
may deteriorate. However, these were not evident from clinical trials with
Optimark.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Central nervous system disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In patients suffering from epilepsy or
brain lesions the likelihood of convulsions during the examination may be
increased. Precautions are necessary when examining these patients (e.g.
monitoring of the patient) and the equipment and medicinal products needed for
the rapid treatment of possible convulsions should be available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Patients with
impaired renal function</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Prior to
administration of Optimark, all patients should be screened for renal dysfunction
by obtaining laboratory tests.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>There have been
reports of nephrogenic systemic fibrosis (NSF) associated with use of Optimark
and some gadolinium-containing contrast agents in patients with acute or
chronic severe renal impairment (GFR &lt;&nbsp;30ml/min/1.73&nbsp;m&sup2;)
and/or acute kidney injury. Optimark is contraindicated in these patients (see
section Contraindications). Patients</span><span lang=EN-GB style='color:black'>
who have had or are undergoing liver transplantation are at particular risk
since the incidence of acute renal failure is high in this group. Therefore,
Optimark must not be used in patients who have had or are undergoing liver
transplantation and in neonates</span><span lang=EN-GB>. </span><span
lang=EN-GB style='color:black'>The risk for development of NSF in patients with
moderate renal impairment</span><span lang=EN-GB> (GFR 30&#8211;59 ml/min/1.73&nbsp;m<sup>2</sup>)
is unknown; therefore, Optimark should only be used after careful <span
style='color:black'>risk-benefit evaluation in patients with moderate renal
impairment</span>. Gadoversetamide is dialysable. Haemodialysis shortly after
Optimark administration may be useful at removing Optimark from the body. There
is no evidence to support the initiation of haemodialysis for prevention or
treatment of NSF in patients not already undergoing haemodialysis.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with baseline renal impairment,
acute kidney injury requiring dialysis has occurred with the use of Optimark.
The risk of acute kidney injury may increase with an increased dose of the
contrast agent. Administer the lowest dose possible for adequate imaging.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><u><span
lang=EN-GB>Children</span></u><u><span lang=EN-GB> and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Optimark must not be administered with an
autoinjector. The required dose should be administered by hand to children </span><span
lang=EN-GB>of 2 to 11 years to avoid overdosage by mistake.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Neonates and infants</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark should
not be used in children below the age of two years. Safety and efficacy have
not been studied in this age group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>As the renal
clearance of gadoversetamide may be impaired in the elderly, it is particularly
important to screen patients aged 65 years and older for renal dysfunction.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains less than 1
mmol sodium (23 mg) per dose of up to 17 ml, i.e. it is essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>10 ml vials and 15 ml vials contain less
than 1 mmol sodium; i.e. they are essentially &#8216;sodium free&#8216;.</span></p>

<p class=MsoNormal><span lang=EN-GB>Higher doses contain 1 mmol sodium or more,
which should be taken into consideration for patients on a controlled sodium
diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>20 ml of the solution contain 28.75 mg
sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><u><span
lang=EN-GB>Serum iron and zinc</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Caution should be exercised because
transient decreases in serum iron and zinc parameters have been observed in
clinical trials. The clinical significance of this is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There are no data from the use of
gadoversetamide in pregnant women. Animal studies do not indicate direct or
indirect harmful effects with respect to reproductive toxicity. Optimark should
not be used during pregnancy unless the clinical condition of the woman
requires use of gadoversetamide.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is unknown whether gadoversetamide is
excreted in human milk. There is insufficient information on the excretion of
gadoversetamide in animal milk. A risk to the suckling child cannot be
excluded. Breast-feeding should be discontinued for at least 24 hours after the
administration of Optimark.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Nonclinical data did not reveal special
hazards for humans based on conventional studies of reproductive toxicity.
Clinical studies on fertility have not been performed.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark should only be administered by
physicians experienced in clinical MRI practice.</span></p>

<p class=MsoNormal><span lang=EN-GB>To enable immediate action in emergencies,
the necessary medicinal products (e.g. epinephrine/ adrenaline, theophylline,
antihistamines, corticosteroids and atropines), endotracheal tube and
ventilator must be immediately available.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The agent should
be administered as a bolus peripheral intravenous injection at a dose of 0.2
ml/kg (100 micromol/kg) body weight. To ensure complete injection of the
contrast medium, the injection should be followed by a 5 ml flush of sodium
chloride 9 mg/ml (0.9 %)</span><span lang=EN-GB> solution for &nbsp;injection.
The imaging procedure should be completed within 1 hour of administration of
the contrast medium.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><i><span
lang=EN-GB>Repeat dose</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>In cranial MRI, if a strong clinical suspicion of a lesion persists
despite a single dose contrast-enhanced MRI or when more accurate information
on the number, size or extent of lesions might influence management or therapy
of the patient, </span><span lang=EN-GB>in subjects with normal renal function,
a second bolus injection of 0.2 ml/kg (100 micromol/kg) may be administered
within 30 minutes of the first injection as it may increase the diagnostic yield
of the examination. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>The safety of repeat doses has not been established in children and
adolescents (2 years and older), in patients with renal impairment, or the
elderly.</span><span lang=EN-GB> The repeat dose is not recommended in these
populations.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Limited data
with other gadolinium contrast agents suggests that for the exclusion of
additional cranial metastases in a patient with a known solitary resectable
metastasis, an MR exam with the injection of 300 micromol/kg body weight of
Optimark may lead to higher diagnostic confidence.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>No dose
adjustment is considered necessary in children more than 2 years of age.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
contraindicated in neonates up to 4 weeks of age. Use of Optimark is not
recommended in children less than 2 years of age<u> </u>because the safety,
efficacy, and impact of immature kidney function have not been studied in this
age group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><i><span
lang=EN-GB>Elderly (aged 65 years and above)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>No dosage
adjustment is considered necessary. Caution should be exercised in elderly
patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>Renal and hepatic
impairment</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark is
contraindicated in patients with severe renal impairment (GFR &lt; 30
ml/min/1.73&nbsp;m&sup2;) and/or acute renal injury and in patients who have
had liver transplantation or in patients in the perioperative liver
transplantation period. Optimark should only be used after careful risk/benefit
evaluation in patients with moderate renal impairment (GFR 30-59 ml/min/1.73&nbsp;m<sup>2</sup>)
at a dose not exceeding 100&nbsp;micromol/kg body weight. More than one dose
should not be used during a scan. Because of the lack of information on
repeated administration, Optimark injections should not be repeated unless the
interval between injections is at least 7 days.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The agent should be administered as a bolus
peripheral intravenous injection. To ensure complete injection of the contrast
medium, the injection should be followed by a 5 ml flush of sodium chloride 9
mg/ml (0.9 %) solution for injection. Insertion of a flexible in-dwelling
venous catheter is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>Optimark must not be administered with an
autoinjector to children of 2 to 11 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Precautions to be taken before handling
or administering the medicinal product</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The container
and the solution should be inspected prior to use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>No formal
interaction studies have been performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>Gadoversetamide has been shown to cause
interference in the measurement of serum calcium using the
ortho-cresolphthalein complexone (OCP) colorimetric method. However, the
administration of gadoversetamide does not cause a true decrease in serum
calcium. In the presence of gadoversetamide, the OCP technique produces an
erroneous, low value for plasma calcium. The magnitude of this measurement
artefact is proportional to the concentration of gadoversetamide in the blood,
and in patients with normal renal clearance accurate values can be obtained
approximately 90 minutes following injection. In patients with compromised
renal function, clearance of gadoversetamide will be slowed and the
interference with calcium determination by OCP prolonged.&nbsp; Gadoversetamide
does not affect other methods of measuring serum calcium, such as the arsenazo
III colorimetric method, atomic absorption spectroscopy, and inductively
coupled plasma mass spectroscopy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Special precautions for disposal and
other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Optimark is intended for single use only;
any unused portions should be discarded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Optimark should
be drawn into the syringe and used immediately. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use the
solution if it is discoloured or particulate matter is present. If
non-disposable equipment is used, scrupulous care should be taken to prevent
residual contamination with traces of cleansing agents. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The product must
be examined before use to confirm that all solids are dissolved and that the
container and closure are un-damaged. If solids remain, the vial must be
discarded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard syringe and unused portion of the
solution after use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><a name="OLE_LINK3"></a><a name="OLE_LINK4"><span
lang=EN-GB>The peel-off tracking label on the vials should be stuck onto the patients
record to enable accurate recording of the gadolinium contrast agent used. The
dose used should also be recorded.</span></a><span lang=EN-GB> If electronic
patient records are used, the name of the product, the batch number and the
dose should be entered into the patient record.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:0in;line-height:14.0pt;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
